- Home
- AIOS vs XRTX Comparison
AIOS vs XRTX Comparison
Compare AIOS & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIOS | XRTX |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | AIOS | XRTX |
|---|---|---|
| Price | $15.10 | $2.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 540.2K | 34.3K |
| Earning Date | 04-20-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.35 |
| 52 Week High | $33.87 | $3.60 |
Technical Indicators
Market Signals| Indicator | AIOS | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.15 | 48.39 |
| Support Level | $13.01 | $1.98 |
| Resistance Level | $18.80 | $3.03 |
| Average True Range (ATR) | 2.08 | 0.32 |
| MACD | -0.68 | -0.06 |
| Stochastic Oscillator | 32.76 | 38.59 |
Price Performance
Historical ComparisonAbout XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.